SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
The COVID-19 vaccine in glass bottles for prevention, immunization, and treatment of coronavirus infection on a green background. Space for text. Concept of medical and vaccine.
COVID-19
FDA’s own report shows no child deaths definitively caused by COVID vaccination
Despite having no definitive data, Sen. Ron Johnson (R-WI) in a letter to health secretary Robert F. Kennedy, Jr. suggested there was a conscious effort by the Biden administration’s FDA to cover up the safety risks of COVID-19 vaccines.
May 19, 2026
 · 
3 min read
 · 
Tristan Manalac
Opportunity of winning. man sees a illuminated trophy door. vector
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval.
May 19, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage. Businessman standing under heavy pressure. Working conditions. Concept of struggle, failure, success, competition, motivation, concentration, crisis, fear Copy space for ad
Opinion
Biotech can’t continue to innovate under strain of Big Pharma market pressures
Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a discovery system built around scientific uncertainty. Structural changes are needed to sustain the sector’s strategic innovation.
May 19, 2026
 · 
5 min read
 · 
Jeremy Levin
Obesity
Deep dive: The oral obesity wars
BioSpace examines how the FDA approval of Eli Lilly’s oral obesity drug Foundayo has ignited a key race with Novo Nordisk.
May 18, 2026
 · 
3 min read
 · 
Heather McKenzie
3D. rocket soaring. Different rockets fly high and stand out. different from others, concept startup idea, new generation, faster work better
Drug Development
Is Revolution ‘the next oncology titan’? Truist analysts make the case
A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter.
May 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Fashionable halftone collage. Concept of partnership, sponsorship,agreement, contract conclusion. Illustration for web banner, social media banner, business presentation, marketing material. Vector illustration
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a new drug class to its early-stage pipeline.
May 18, 2026
 · 
2 min read
 · 
Gabrielle Masson
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit its 2030 goal of $80 billion in revenue.
May 18, 2026
 · 
1 min read
 · 
Tristan Manalac
Business people and concepts vector art exit
Government
Prasad ally Szarama exits CBER after 3 weeks as FDA cleanout continues
After less than three weeks on the job, Katherine Szarama is being replaced by Karim Mikhail as acting head of the Center for Biologics Evaluation and Research. Mikhail had previously spent more than 20 years at Merck and joined the FDA last year.
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also noting last year’s Phase 3 failure in chronic obstructive pulmonary disease.
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS